Dispersal evolution in neoplasms: The role of disregulated metabolism in the evolution of cell motility

Cancer Prevention Research

Volumn 5, Issue 2, 2012, Pages 266-275

  Aktipis, C Athena ^a,b,c   Maley, Carlo C ^b   Pepper, John W ^a,b,d  

^a University of Arizona   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MOTILITY; CELL MOTION; CELL TYPE; CONCEPTUAL FRAMEWORK; METABOLIC DISORDER; METABOLIC RATE; METASTASIS; PRIORITY JOURNAL;

BIOLOGICAL EVOLUTION; CELL MOVEMENT; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84857677326     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0004     Document Type: Article

References (48)

1. Cairns J. Mutation selection and the natural history of cancer. Nature 1975;255:197-200.
2. Merlo LF, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006;6:924-35. (Pubitemid 44862677)
3. Smalley KSM, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol 2005;15:451-9. (Pubitemid 41318045)
4. Ye C, Stevens JB, Liu G, Bremer SW, Jaiswal AS, Ye KJ, et al. Genome based cell population heterogeneity promotes tumorigenicity: the evolutionary mechanism of cancer. J Cell Physiol 2009;219:288-300.
5. Pepper JW, Findlay SC, Kassen R, Spencer SL, Maley CC. Cancer research meets evolutionary biology. Evol Appl 2009;2:62-70.
6. Wells A. Motility in tumor invasion and metastasis-an overview. Dordrecht, The Netherlands: Springer; 2006. p. 1-23.
7. Gatenby RA, Gawlinski ET. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 2003;63:3847-54. (Pubitemid 36917892)
8. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-7.
9. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009;25:30-8.
10. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47. (Pubitemid 37328806)
11. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9:4-9. (Pubitemid 39658340)
12. Hardin G. The tragedy of the commons. Science 1968;162:1243-8.
13. Rankin DJ, Bargum K, Kokko H. The tragedy of the commons in evolutionary biology. Trends Ecol Evol 2007;22:643-51. (Pubitemid 350180145)
14. Dawes RM. Social dilemmas. Annu Rev Psychol 1980;31:169-93.
15. Hochberg M, Rankin D, Taborsky M. The coevolution of cooperation and dispersal in social groups and its implications for the emergence of multicellularity. BMC Evol Biol 2008;8:238.
16. Duckworth RA. Adaptive dispersal strategies and the dynamics of a range expansion. Am Nat 2008;172:S4-S17.
17. Weinhouse S, Warburg O, Burk D, Schade AL. On respiratory impairment in cancer cells. [cited 1956]. Available from: http://adsabs.harvard.edu/abs/ 1956Sci...124.267W
18. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
19. Elser JJ, Kyle MM, Smith MS, Nagy JD. Biological stoichiometry in human cancer. PLoS One 2007;2:e1028.
20. Wilensky U. NetLogo: center for connected learning and computer-based modeling. Evanton, Illinois: Northwestern University; 1999.
21. Grimm V, Berger U, Bastiansen F, Eliassen S, Ginot V, Giske J, et al. A standard protocol for describing individual-based and agent-based models. Ecol Modell 2006;198:115-26. (Pubitemid 44308373)
22. Grimm V, Railsback SF. Individual-based modeling and ecology. Princeton: Princeton University Press; 2005.
23. Pfeiffer T, Bonhoeffer S. An evolutionary scenario for the transition to undifferentiated multicellularity. Proc Natl Acad Sci U S A 2003;100:1095-8. (Pubitemid 36183961)
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
25. Anderson A, Weaver A, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006;127:905-15. (Pubitemid 44792251)
26. Anderson A, Rejniak KA, Gerlee P, Quaranta V. Microenvironment driven invasion: a multiscale multimodel investigation. J Math Biol 2009;58:579-624.
27. Basanta D, Hatzikirou H, Deutsch A. Studying the emergence of invasiveness in tumours using game theory. Eur Phys J B- Condensed Matter and Complex Systems 2008;63:393-7.
28. Foster KR. The sociobiology of molecular systems. Nat Rev Genet 2011;12:193-203.
29. Dieckmann U. The evolutionary ecology of dispersal. Trends Ecol Evol 1999;14:88-90. (Pubitemid 29135078)
30. Weinhouse S. The Warburg hypothesis fifty years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976;87:115-26.
31. Patel AA, Gawlinski ET, Lemieux SK, Gatenby RA. Acellular automaton model of early tumor growth and invasion: the effects of native tissue vascularity and increased anaerobic tumor metabolism. J Theor Biol 2001;213:315-31. (Pubitemid 34014402)
32. Vincent TL, Gatenby RA. An evolutionary model for initiation, promotion, and progression in carcinogenesis. Int J Oncol 2008;32:729-37. (Pubitemid 351780583)
33. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980;303:878-80.
34. Weinberg RA. Biology of Cancer. New York, New York: Garland Science; 2006.
35. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27. (Pubitemid 36999703)
36. Osborne CK, Yochmowitz MG, Knight WA III, McGuire WL. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-8. (Pubitemid 11205652)
37. Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA. The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors. Breast 2009;18:351-5.
38. Williams JB, Miller RA, Harper JM, Wiersma P. Functional linkages for the pace of life, life-history, and environment in birds. Integr Comp Biol 2010;50:855-68.
39. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res 2010;704:152-9.
40. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85.
41. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996;313 (Pt 1):17-29. (Pubitemid 26013419)
42. Pepper JW. Defeating pathogen drug resistance: guidance from evolutionary theory. [cited 2009]. Available from: http://www.bioone.org/doi/abs/10.1111/j. 1558-5646.2008.00525.x
43. Pepper JW. Somatic evolution of acquired drug resistance in cancer. In: Gioeli, editor. Targeted therapies: mechanisms of resistance. New York, New York: Springer; 2011. p. 127-34.
44. Chowdhury TA. Diabetes and cancer. QJM 2010;103:905-15.
45. Remedi MS, Nichols CG. Hyperinsulinism and diabetes: genetic dissection of b cell metabolism-excitation coupling in mice. Cell Metab 2009;10:442-53.
46. Maley CC, Reid BJ, Forrest S. Cancer prevention strategies that address the evolutionary dynamics of neoplastic cells: simulating benign cell boosters and selection for chemosensitivity. Cancer Epidemiol Biomarkers Prev 2004;13:1375-84. (Pubitemid 39071564)
47. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839-51.
48. Liotta LA, Kohn EC. Cancer's deadly signature. Nat Genet 2003;33:10-1. (Pubitemid 36068672)